Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 1.00 |
| ▸ | XDH | P47989 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | NPC1 | O15118 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | FLT3 | P36888 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | APP | P05067 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metochalcone SCHEMBL29412184 | 1.00 | ABCG2 (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| Metochalcone SCHEMBL4957703 | 1.00 | ABCG2 (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| Metochalcone SCHEMBL29412185 | 1.00 | ABCG2 (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL21527710 | 0.93 | XDH (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL30138844 | 0.93 | ABCG2 (0.89) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL21527708 | 0.93 | XDH (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL29443572 | 0.92 | ABCG2 (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL18742804 | 0.92 | ABCG2 (0.86) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL4030793 | 0.91 | MAPT (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 | |
| SCHEMBL4030789 | 0.91 | MAPT (1.00) | ABCG2MAPTTNFRSF1AXDHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 767 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | claimed |
| EP-3562803-B1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2025-10-15 | — | — | EP | claimed |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YewSavin, Inc. (US) | 2025-03-20 | — | — | US | claimed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | claimed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | claimed |
| CN-115990147-A | Application of metochalcone in preparation of tumor metastasis inhibiting drugs | 四川大学 | 2023-04-21 | — | — | CN | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| WO-2004075857-A2 | COMPOSITIONS, COMBINATIONS, AND METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND OTHER ASSOCIATED CONDITIONS | PHARMACIA CORPORATION (US) | 2004-09-10 | — | — | WO | claimed |
| CN-1473567-A | Combined therapeutic method including acrivastine and antihypertensive | ������ҩ������˾ | 2004-02-11 | — | — | CN | claimed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | ABCG2 2664/4885MAPT 653/4885TNFRSF1A 4014/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885MAPT 3297/4885TNFRSF1A 2669/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885MAPT 3512/4885TNFRSF1A 3485/4885 |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, TFPI, SERPINE1 | ABCG2 3458/4885MAPT 3522/4885TNFRSF1A 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.